BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...Replimune’s stock dipped $0.61 to $20.61 Thursday. Other companies raising follow-on capital this week include Kezar Life Sciences Inc....
...Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx Inc. Fate Therapeutics Inc. CareDx Inc. Retrophin Inc. Replimune Group Inc. Kezar Life Sciences Inc. Mustang...
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

...Schoene was president and CEO of Elevance Renewable Sciences Inc. Cancer and autoimmune disease company Kezar Life Sciences Inc....
...Sawka, BioCentury Staff GenMark Diagnostics Inc. SutroVax Inc. Illumina Inc. Arrowhead Pharmaceuticals Inc. Tessa Therapeutics Pte. Ltd. Impel NeuroPharma Inc. Codexis Inc. Imara Inc. Kezar Life Sciences Inc....
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

...through the sale of 27.8 million shares at $3.25, while cancer and autoimmune disease company Kezar Life Sciences Inc....
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...Transporters identified in new targets that were not related to metabolism were SEC61 and IPO1. Kezar Life Sciences Inc....
BioCentury | Mar 6, 2019
Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

...was VP, chromatography and mass spectrometry, EMEA, at Thermo Fisher Scientific Inc. (NYSE:TMO). Immunology company Kezar Life Sciences Inc....
BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:MGTA) 6/20/18 $100.0 $515.6 $459.2 -11% Xeris Pharmaceuticals Inc. (NASDAQ:XERS) 6/20/18 $98.3 $308.9 $380.9 23% Kezar Life Sciences Inc....
BioCentury | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

...start a Phase II study of the therapy to treat sickle cell disease. Immunology company Kezar Life Sciences Inc....
...Mass. Kezar Life Sciences Inc. (NASDAQ:KZR), South San Francisco, Calif. Xeris Pharmaceuticals Inc. (NASDAQ:XERS), Austin, Texas Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta...
BioCentury | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

...start a Phase II study of the therapy to treat sickle cell disease. Immunology company Kezar Life Sciences Inc....
...Glucagon Rescue Pen, which delivers glucagon via an auto-injector to treat severe hypoglycemia. Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta...
BioCentury | Jun 1, 2018
Financial News

Kezar files to raise $80.5M in IPO on NASDAQ

...last year led by Cormorant Asset Management and Morningside Ventures. Kezar Life Sciences Inc., South San Francisco, Calif. Allison Johnson KZR-616 Kezar Life Sciences...
BioCentury | May 25, 2018
Financial News

Immunoproteasome company Kezar files for $80.5M IPO

...B round last year led by Cormorant Asset Management and Morningside Ventures. Allison Johnson KZR-616 Amgen Inc. Cormorant Asset Management Kezar Life Sciences Morningside...
Items per page:
1 - 10 of 16
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...Replimune’s stock dipped $0.61 to $20.61 Thursday. Other companies raising follow-on capital this week include Kezar Life Sciences Inc....
...Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx Inc. Fate Therapeutics Inc. CareDx Inc. Retrophin Inc. Replimune Group Inc. Kezar Life Sciences Inc. Mustang...
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

...Schoene was president and CEO of Elevance Renewable Sciences Inc. Cancer and autoimmune disease company Kezar Life Sciences Inc....
...Sawka, BioCentury Staff GenMark Diagnostics Inc. SutroVax Inc. Illumina Inc. Arrowhead Pharmaceuticals Inc. Tessa Therapeutics Pte. Ltd. Impel NeuroPharma Inc. Codexis Inc. Imara Inc. Kezar Life Sciences Inc....
BioCentury | Feb 6, 2020
Finance

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

...through the sale of 27.8 million shares at $3.25, while cancer and autoimmune disease company Kezar Life Sciences Inc....
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...Transporters identified in new targets that were not related to metabolism were SEC61 and IPO1. Kezar Life Sciences Inc....
BioCentury | Mar 6, 2019
Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

...was VP, chromatography and mass spectrometry, EMEA, at Thermo Fisher Scientific Inc. (NYSE:TMO). Immunology company Kezar Life Sciences Inc....
BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:MGTA) 6/20/18 $100.0 $515.6 $459.2 -11% Xeris Pharmaceuticals Inc. (NASDAQ:XERS) 6/20/18 $98.3 $308.9 $380.9 23% Kezar Life Sciences Inc....
BioCentury | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

...start a Phase II study of the therapy to treat sickle cell disease. Immunology company Kezar Life Sciences Inc....
...Mass. Kezar Life Sciences Inc. (NASDAQ:KZR), South San Francisco, Calif. Xeris Pharmaceuticals Inc. (NASDAQ:XERS), Austin, Texas Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta...
BioCentury | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

...start a Phase II study of the therapy to treat sickle cell disease. Immunology company Kezar Life Sciences Inc....
...Glucagon Rescue Pen, which delivers glucagon via an auto-injector to treat severe hypoglycemia. Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta...
BioCentury | Jun 1, 2018
Financial News

Kezar files to raise $80.5M in IPO on NASDAQ

...last year led by Cormorant Asset Management and Morningside Ventures. Kezar Life Sciences Inc., South San Francisco, Calif. Allison Johnson KZR-616 Kezar Life Sciences...
BioCentury | May 25, 2018
Financial News

Immunoproteasome company Kezar files for $80.5M IPO

...B round last year led by Cormorant Asset Management and Morningside Ventures. Allison Johnson KZR-616 Amgen Inc. Cormorant Asset Management Kezar Life Sciences Morningside...
Items per page:
1 - 10 of 16